Tenofovir (all routes except local)

Early intrauterine death (< 22 weeks)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S5153
R13439		 Pintye, 2017 Pregnancy loss (< 20 weeks) at least 1st trimester prospective cohort exposed to other treatment, sick Adjustment: Yes Control group: zidovudine/lamivudine-based Exposed group: TDF/lamivudine-based Indication: PrEP 1.11 [0.25;4.88] 13/-   6/- 19 -
ref
S5265
R13632		 Mugo, 2014 Pregnancy losses <20 weeks’ gestation early pregnancy randomized controlled trial unexposed, sick Adjustment: Randomisation Control group: Unexposed, sick Exposed group: TDF (only) Indication: PrEP 0.86 [0.50;1.49] C 49/174   30/96 79 174
ref
S5122
R13298		 Gibb, 2012 Miscarriages/terminations (< 22 weeks) throughout pregnancy prospective cohort exposed to other treatment, sick Adjustment: No Control group: zidovudine/lamivudine-based Exposed group: TDF/zidovudine/lamivudine Indication: HIV 1.13 [0.71;1.81] C 90/251   38/115 128 251
ref
Total 3 studies 1.01 [0.72;1.43] 226 425
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Pintye, 2017Pintye, 2017 1.11[0.25; 4.88]19-5%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Mugo, 2014Mugo, 2014 0.86[0.50; 1.49]7917440%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Gibb, 2012Gibb, 2012 1.13[0.71; 1.81]12825154%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (3 studies) I2 = 0% 1.01[0.72; 1.43]2264250.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.13[0.72; 1.76]1472510%NAPintye, 2017 Gibb, 2012 2 case control studiescase control studies 0 RCTRCT 0.86[0.50; 1.49]79174 -NAMugo, 2014 1 Type of controls unexposed, sickunexposed, sick 0.86[0.50; 1.49]79174 -NAMugo, 2014 1 exposed to other treatment, sickexposed to other treatment, sick 1.13[0.72; 1.76]1472510%NAPintye, 2017 Gibb, 2012 2 Tags Adjustment   - No  - No 1.13[0.71; 1.81]128251 -NAGibb, 2012 1   - Randomisation  - Randomisation 0.86[0.50; 1.49]79174 -NAMugo, 2014 1   - Yes  - Yes 1.11[0.25; 4.90]19- -NAPintye, 2017 1 Control group   - Unexposed, sick  - Unexposed, sick 0.86[0.50; 1.49]79174 -NAMugo, 2014 1   - zidovudine/lamivudine-based  - zidovudine/lamivudine-based 1.13[0.72; 1.76]1472510%NAPintye, 2017 Gibb, 2012 2 Exposed group   - TDF (only)  - TDF (only) 0.86[0.50; 1.49]79174 -NAMugo, 2014 1   - TDF/lamivudine-based  - TDF/lamivudine-based 1.11[0.25; 4.90]19- -NAPintye, 2017 1   - TDF/zidovudine/lamivudine  - TDF/zidovudine/lamivudine 1.13[0.71; 1.81]128251 -NAGibb, 2012 1 Indication   - HIV  - HIV 1.13[0.71; 1.81]128251 -NAGibb, 2012 1   - PrEP  - PrEP 0.89[0.53; 1.48]981740%NAPintye, 2017 Mugo, 2014 2 All studiesAll studies 1.01[0.72; 1.43]2264250%NAPintye, 2017 Mugo, 2014 Gibb, 2012 30.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 0.86[0.50; 1.49]79174 -NAMugo, 2014 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.13[0.72; 1.76]1472510%NAPintye, 2017 Gibb, 2012 20.510.01.0